Analyst & Firm | Company | Price | Rating & Price Target | Upside / Downside | Success Rate | Average Return | Action | Date | Article |
---|---|---|---|---|---|---|---|---|---|
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $102 | ― | 21.60% | Downgraded | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $270 | ― | 8.60% | Reiterated | ||||
ZIM Integrated Shipping Services | SELL $13.9→$16.5 | ― | -5.00% | Reiterated | Barclays Sticks to Its Sell Rating for ZIM Integrated Shipping Services (ZIM) | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $20→$12 | ― | 0.20% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $11.5→$11.8 | ― | 1.20% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $6 | ― | 0.20% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $3.2→$3.1 | ― | 10.10% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $70 | ― | 13.00% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $52 | ― | 17.90% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL $4.8→$3.9 | ― | 0.60% | Downgraded | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $515 | ― | 11.30% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $20 | ― | 6.60% | Assigned | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $130 | ― | 35.10% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $19→$20 | ― | 16.70% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $173→$250 | ― | 12.10% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $23 | ― | 17.80% | Initiated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $14 | ― | 17.80% | Initiated | ||||
Zymeworks | HOLD $12 | ― | -17.40% | Reiterated | Zymeworks Hold Rating: Balancing FDA Milestones with Market Valuation and Future Risks | ||||
Replimune Group | BUY $17 | ― | -17.40% | Reiterated | Buy Recommendation for Replimune Group: Promising Developments and Clinical Results of RP1 Treatment | ||||
Rallybio | BUY $5 | ― | -13.80% | Reiterated | Rallybio's Promising Advances and Financial Projections Earn 'Buy' Rating from Analyst | ||||
Korro Bio | BUY $115 | ― | -13.80% | Reiterated | Mitchell Kapoor Reaffirms Buy Rating for Korro Bio Amid Promising Developments in KRRO-110 Treatment | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $50 | ― | 3.50% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $90→$98 | ― | 2.70% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $164 | ― | 6.80% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $180 | ― | 5.90% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $125 | ― | 5.20% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $29→$30 | ― | 6.80% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $127→$132 | ― | 6.10% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $320→$375 | ― | 2.60% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $181 | ― | 0.70% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $74→$83 | ― | 6.60% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $26→$28 | ― | 0.70% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $330→$369 | ― | 12.70% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $685→$730 | ― | 16.10% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $610 | ― | 17.80% | Initiated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $55 | ― | 4.50% | Initiated | ||||
Life Time Group Holdings | BUY $29 | ― | -14.10% | Initiated | Life Time Group initiated with an Outperform at Evercore ISI | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $205→$215 | ― | 11.80% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $24→$28 | ― | 33.70% | Reiterated | ||||
Innovid | HOLD | ― | -2.70% | Downgraded | Innovid downgraded to Hold from Buy at Needham | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $37→$44 | ― | 6.80% | Assigned | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $19 | ― | 8.60% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $32 | ― | 8.60% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $178 | ― | 7.40% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $350 | ― | 0.60% | Assigned | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $135 | ― | 26.50% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $140 | ― | 25.40% | Assigned | ||||
Gap Inc | BUY $30 | ― | -0.20% | Assigned | Gap Inc's Strong Performance and Promising Outlook Justify Buy Rating | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $135 | ― | 16.90% | Assigned | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $30 | ― | 24.00% | Assigned |